Arvinas, Inc. (NasdaqGS: ARVN)
Health Care · Pharmaceuticals · US
$9.34
-0.27% today · +25.2% 1Y
Arvinas, Inc. (NasdaqGS: ARVN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $612.34M and employs 246 people.
Over the last twelve months the share price has gained 25.2%, trading between 6.97 and 14.51.
Tweenvest scores Arvinas, Inc. across four factors: quality 34/100, value 57/100, growth 100/100. Its strongest factor is growth.
ARVN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $612.34M
- Revenue (TTM)
- $316.70M
- P/E
- 70.06
- EPS
- 0.13
- Dividend yield
- —
- Beta (5Y)
- 1.74
- 52-week high
- $14.51
- 52-week low
- $6.97
- Avg volume (3M)
- —
- Shares outstanding
- 65.39M
- Employees
- 246
- Next earnings
- —
About Arvinas, Inc.
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
- ISIN
- US04335A1051
- Founded
- 2013
- Listed since
- Sep 27, 2018
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.